↓ Skip to main content
What is this page? Embed badge

HCV: The Journey from Discovery to a Cure

Overview of attention for book
Cover of 'HCV: The Journey from Discovery to a Cure'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 43 The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa ® )
  3. Altmetric Badge
    Chapter 44 Discovery of Elbasvir
  4. Altmetric Badge
    Chapter 45 NS5A as a Target for HCV Drug Discovery
  5. Altmetric Badge
    Chapter 46 Evolution of HCV NS4B Inhibitors
  6. Altmetric Badge
    Chapter 47 The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex
  7. Altmetric Badge
    Chapter 48 The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni ® )
  8. Altmetric Badge
    Chapter 49 The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi ® )
  9. Altmetric Badge
    Chapter 50 HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments
  10. Altmetric Badge
    Chapter 52 The Benefit of Direct-Acting Antiviral HCV Cure Therapies
  11. Altmetric Badge
    Chapter 54 Development of ZEPATIER ®
  12. Altmetric Badge
    Chapter 56 Cure and Control: What Will It Take to Eliminate HCV?
  13. Altmetric Badge
    Chapter 60 Clinical Development of Viekira Pak to Mavyret
  14. Altmetric Badge
    Chapter 63 Real-World Evidence and Hepatitis C
  15. Altmetric Badge
    Chapter 64 The Evolution of Clinical Trials for Hepatitis C
  16. Altmetric Badge
    Chapter 65 Perspectives on HCV Cure
  17. Altmetric Badge
    Chapter 66 The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni ®
  18. Altmetric Badge
    Chapter 67 The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa and Vosevi ®
Attention for Chapter 50: HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments
Altmetric Badge

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
4 Mendeley
Summary Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments
Chapter number 50
Book title
HCV: The Journey from Discovery to a Cure
Published by
Springer, Cham, January 2019
DOI 10.1007/7355_2018_50
Book ISBNs
978-3-03-028399-5, 978-3-03-028400-8
Authors

Rolf Wagner, David A. DeGoey, John T. Randolph, Allan C. Krueger, Mark A. Matulenko, Warren M. Kati

View on publisher site
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 1 25%
Student > Postgraduate 1 25%
Student > Master 1 25%
Unknown 1 25%
Readers by discipline Count As %
Chemistry 2 50%
Medicine and Dentistry 1 25%
Unknown 1 25%

This page is provided by Altmetric.